← Back to patent-cliff list
IkT-001Pro
Tier C — Watch / tradeIkT-001Pro
Inhibikase Therapeutics Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Bcr-Abl, PDGFR
Indications (approved)：Pulmonary arterial hypertension, Chronic myeloid leukaemia
Regional status
US
Phase III
2026-04-23
EU
Phase III
2026-04-23
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of IkT-001Pro?
Approved indications include: Pulmonary arterial hypertension, Chronic myeloid leukaemia.
When does the IkT-001Pro patent expire?
No public expiry year is available for IkT-001Pro yet; this page updates once verified.
How do I get a quote for IkT-001Pro intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-01